Introduction
In recent years, several new drugs have been introduced to treat seizures in adults and children. In the majority of patients, these drugs suppress epileptic seizures without causing unacceptable side effects, as has been shown in the necessary registration studies (for a review, see Mohanray and Brodie, 2003) . 1 In childhood epilepsy, seizure control and favourable safety profile are not the only outcome parameters that are important in clinical practice. A major concern is a possible negative effect of anti-epileptic drugs on cognitive functions in the developing brain. These issues are not always dealt with in the registration studies. For clinical practice, post-registration experience with the new Seizure (2005) Summary We examined the efficacy, optimum dosage and adverse effects of levetiracetam in two prospective trials in children with epilepsy. In the add-on trial, 67 children between 6 months and 16 years were included. In the mono-therapy trial, 10 children between 4 years and 16 years were included. Levetiracetam was titrated up to an optimal dosage for every individual patient, depending on efficacy and tolerability, and reflecting clinical practice. The range of dosages used was between 12 and 62 mg/kg/day, with a median of 33 mg/kg/day. Overall, 20 weeks after the start of levetiracetam, there was a median seizure reduction of 60% (add-on trial 50%; mono-therapy trial 81%). Levetiracetam was equally effective for partial and generalized seizures. Side effects were less common in the mono-therapy trial. Tiredness (7.8%) and aggressiveness (5%) were the most common side effects, and were doserelated, but were no reason to discontinue levetiracetam. In 25% of the children, a positive effect was seen on behaviour and/or alertness. This could not be related directly to seizure control. Overall, these two clinical trials confirm that levetiracetam is a broad spectrum anti-epileptic drug with a favourable safety profile. The positive effect on behaviour needs further quantitative study. # 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
anti-epileptic drugs is also important to find new indications, best dosage, possible combination therapies, effect in specific epilepsy syndromes and previously unrecognized adverse effects.
Levetiracetam is new anti-epileptic drug with proven efficacy in partial and generalized seizures, both in adults and children, and with a good safety profile. [2] [3] [4] [5] [6] [7] [8] [9] [10] In this prospective clinical study, we evaluated the effect of levetiracetam in 77 children with a variety of childhood epilepsy syndromes with both partial and generalized seizures. Most children had difficult to treat epilepsy. Besides seizure control, special attention was paid to the effect of levetiracetam on behaviour and alertness. The medication was provided by UCB in 2 'investigator-driven' clinical studies, so that we could also study the effect of levetiracetam for non-registered indications.
Methods
The two study protocols were approved by the Ethical Committee of our University Hospital.
Add-on study
In the add-on study, children >6 months could be included. In a baseline period of 4 weeks before inclusion, all patients had at least four seizures that could be adequately described by the parents or the care-givers. We used this clinical information to categorize the predominant seizure type as partial or generalized, following the ILAE criteria. In patients with both partial and generalized seizures, we used the classification 'mixed'.
Levetiracetam was started at a dosage of 10 mg/ kg/day, given in two equal dosages. Levetiracetam was increased weekly by 10 mg/kg up to a maximum of 60 mg/kg/day, depending on efficacy and tolerability. Background anti-epileptic drugs were kept stable for the first 12 weeks of the study.
Mono-therapy trial
In the mono-therapy trial, children >4 years could be included. In this study, levetiracetam was the first drug that was administered or was the second drug that was tried after discontinuing a first, ineffective, anti-epileptic drug. Inclusion criteria, classification of seizure type and levetiracetam dosage schedule were otherwise the same as in the add-on trial.
In both studies, children were seen and examined at inclusion, after 4, 8, 12 and 20 weeks. A structured data file and questionnaire were used to collect the necessary data. Patient diaries and detailed history were used to calculate seizure frequency as accurately as possible. Overall quality of life was scored by the parents on a scale from 0 to 10, with 10 being the maximum. Their judgment on this scale represents a combination of efficacy and tolerability.
At 20 weeks, or at the last follow-up visit if levetiracetam was discontinued before 20 weeks, an analysis of effect and tolerability was performed. Percentage seizure reduction was calculated for every child and for the different seizure types.
Results
In Table 1 , the two study populations are presented. Sixty-seven and 10 children with a median age of 8 and 9 years were included in the add-on and the mono-therapy trial respectively. In the add-on trial there were 18 children below the age of 4 years, including 6 below the age of 1 year.
In the add-on study, no aetiology for the epilepsy was found in 26 children. These children presented with partial (n = 12), myoclonic (n = 7), multifocal (n = 3) and generalized (n = 4) seizures. In the other 41 children of the add-on group, the aetiology was variable: West syndrome (2), Lennox-Gastaut syndrome (7), cortical malformations (6), tuberous sclerosis (3), severe myoclonic epilepsy of infancy (2), acquired brain lesions (9), metabolic disorders (3), isolated mental retardation and autism (5), tumour (3), ESES (1). The fact that 85% of the children in that group were mentally retarded underlines the severity of their neurological dysfunction. The number of background anti-epileptic drugs was 2 or more in 76% of the children, indicative of the refractory character of their epilepsy.
In the mono-therapy trial, six children presented with generalized seizures: two with classical childhood absences, two with myoclonic seizures and two with tonic/clonic seizures. In the four children with partial seizures, one child was classified with benign rolandic epilepsy and two with complex partial seizures in the context of cerebral palsy. These were the only two children in that group with mental retardation.
In both groups, the distribution between generalized and partial seizures was comparable.
The range of prescribed levetiracetam dosages was large: 12-62 mg/kg/day for the total group. The median dosage in the mono-therapy trial (29 mg/kg/day) was somewhat, but not statistically, lower than in the add-on trial (33 mg/kg/day).
The retention rate at 20 weeks was high in both groups. Overall, 75% (58/77) of the children com-pleted the 20 weeks study period. Levetiracetam was stopped prematurely because of lack of efficacy in the 17 of the 19 children. Nine of the 19 children who did not complete the trial, stopped after visit 3 (8 weeks) and the remaining 10 after visit 4 (12 weeks). The total exposure duration to levetiracetam, was 338 months, compared to the theoretical 385 months if every child would have ended the full trial (77 Â 5 months).
In Table 2 , the efficacy of levetiracetam in the two study groups is shown. In the add-on trial, there was a median seizure reduction of 50%. In 33/67 (49%) children, a seizure reduction of >50% was observed. Three of the 67 children became seizure free. In the mono-therapy trial, results were even better. In 9/10 children, there was a seizure reduction of >50% was found for 9/10 children and the median seizure reduction was 81%. 2 children became seizure free in that group. Both were previously untreated; one was diagnosed with childhood absence epilepsy and the other with benign rolandic epilepsy.
In the add-on group an increase of seizure frequency was observed in 10/67 (15%) children. In these 10 children, the median increase was 50%, with a range between 18% and 420%. In 3 of these 10 children, the number of seizures was more than twice the baseline frequency (200%). No reason for this phenomenon could be identified in our data: there was no effect of age, dosage, background antiepileptic drugs, seizure type or epilepsy syndrome.
Looking at partial and generalized seizures separately, no significant differences could be found (see Table 2 ). This was confirmed in a separate analysis on the efficacy of levetiracetam in the different epilepsy syndromes: there were no epilepsy syndromes in which levetiracetam had a specific efficacy profile. Also, no combination with a particular anti-epileptic drug proved to be superior or inferior.
The number of reported adverse effects was very low in both cohorts and in only two children these adverse effects were the actual reason to stop the medication ( Table 3 ). The most frequently reported adverse effect was 'tiredness', or 'increased sleepiness' as expressed by some parents. This adverse effect was seen only in the add-on group and was related to the levetiracetam dosage. In 4/6 children with 'tiredness', the levetiracetam dosage was >45 mg/kg/day. In only one child this adverse effect was the reason to discontinue the medication. In four other children, the parents reported a change in behaviour with increased impulsiveness and aggressiveness. However, this was not a reason to discontinue the medication. One other child stopped the medication because of recurrent headaches. In the mono-therapy trial, anorexia was reported in one child.
We also systematically asked for possible positive effects of the medication on alertness and behaviour. We could not test this quantitatively in this study group with many severely retarded children, and therefore, a structured questionnaire was used for this purpose. In about 1/4 children there was a positive effect on alertness and/or behaviour. A better alertness typically indicated a better verbal or non-verbal communication between the caregivers and the child. Better behaviour in most children meant that the child could be better handled and structured. In most cases, the children were calmer. These positive effects after the introduction of levetiracetam were not always related to seizure frequency reduction. In 7/18 children with increased alertness, there was a seizure reduction of less than 50%. Also, in 7/16 children with better behaviour, seizure reduction was less than 50%.
Overall quality of life was expressed on a quantitative scale from 0 to 10. This scale was completed by 49/67 parents in the add-on group and in 10/10 parents in the mono-therapy trial. The parents were instructed that a '10' would mean that levetiracetam was 'the wonder medication' for the child. The median score was 6 in the add-on group and 8 in the mono-therapy trial. Range was very large in the addon group (0-9), while scores were 6 or higher in the mono-therapy trial.
Discussion and conclusions
This study is based on clinical practice and provides new insights in the use, efficacy and side effects of Overall quality of life n = 10 n = 49 n = 59 Median score 8/10 6/10 7/10 Range score 6-9 0 -9 0 -9 levetiracetam in childhood epilepsy. In contrast with the regulatory studies, we titrated levetiracetam to an individual optimal dosage and were not limited by age limit, epilepsy syndrome or seizure type. Our data basically confirm that levetiracetam is a broad spectrum anti-epileptic drug with a safe profile. In our add-on trial, children refractory to 'first line' anti-epileptic drugs were included. Many of these patients were known with catastrophic epilepsies, such as the Lennox-Gastaut syndrome. Also, many children were between 6 months and 4 years, an age range for which no systematic data are available yet. In our smaller mono-therapy trial, children with more benign epilepsy syndromes were included. In about 50% of the patients in the add-on trial, there was a seizure reduction of >50%. These numbers were significantly higher in the mono-therapy trial, with 90% of the patients showing a seizure reduction of >50% and 20% becoming seizure free. Only limited data are available on mono-therapy use of levetiracetam in children. Ben-Menachem reported the results of two mono-therapy trials in adults, showing a good efficacy and safety profile.
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In the study of Cohen, three adult refractory patients with primary generalized epilepsy became seizure free on levetiracetam mono-therapy. 12 Bello-Espinoza and Roberts successfully used levetiracetam as mono-therapy in three children with benign rolandic epilepsy. 13 Both in the add-on trial and in the mono-therapy trial, levetiracetam was effective in partial and generalized seizures. Especially the data for generalized seizures are interesting since many childhood epileptic syndromes, and especially the catastrophic epilepsies, are characterized by the presence of generalized seizures. Most previous studies on levetiracetam in childhood epilepsy, were focused on partial seizures. [7] [8] [9] In our previous study, we could show a beneficial effect of levetiracetam on generalized and especially on myoclonic seizures. 9 This was also confirmed in the study of Wheless and Ng. 8 and in the review paper by Glauser and Dulac. 7 The individual dosages in both groups were very variable (12-62 mg/kg/day), indicating that a preset dosage of for instance 30-40 mg/kg/day is perhaps not an optimal solution for the individual patient. In the mono-therapy trial, for instance, dosages tended to be lower.
In 15% of the patients of the add-on trial an increase of the number of seizures was found. Similar findings were reported in the study of Nakken et al. 14 In their study, this increase was seen most frequently in mentally retarded patients, in the beginning of the therapy and on rather high doses. We could not find a similar explanation for this phenomenon, although 85% of our patients were indeed mentally retarded. This increase was not seen in the last weeks before analysis which could indicate a tolerance effect. A recent study showed that there was a sustained effect of levetiracetam in (adult) patients. 15 There was also no relationship with finale-dosage. It is possible that this increase may reflect the natural course in these difficult epilepsy syndromes in non-responsive patients.
We found significantly fewer adverse effects than in the registration trials, and these few adverse effects were rarely the reason to stop levetiracetam. Adverse effects appeared to be related to final-dosage, again emphasizing an individualized approach. Although the sample is small, patients in the mono-therapy trial did not show any adverse effect. In a recent study, behavioural problems were seen in about 7% of the 53 adult patients and were the main reason for discontinuation. 16 Potential risk factors, the study identified pre-treatment psychiatric problems and symptomatic generalized epilepsy. Our study in children actually yields similar percentages: in 6% of the children in the add-on study, more aggressive behaviour was noted by the parents. However, this was not a reason for drug discontinuation in these children.
In the opinion of many parents the positive effects on behaviour and especially on alertness were the most important effect. In 1/4 of the patients, a positive effect was reported, although these high numbers might represent a bias, since these effects were specifically asked for. This positive effect was also noted by Herranz et al. in their study in 43 children. 10 In 34.9% there was an improvement in social behaviour and in cognitive skills. In the study of Wheless and Ng, a similar positive effect on cognition was noted. The mechanism of this positive effect is difficult to explain. The most obvious reason would be that increased alertness or better behaviour is related to seizure control, or perhaps to a decrease of epileptic EEG abnormalities. The fact that this positive effect was not directly related to efficacy in our study, makes this hypothesis less likely as a major determinant. It remains to be determined whether levetiracetam has a genuine positive effect on behavioural parameters. Neuropsychological and neurophysiological studies are needed to explore this behavioural/cognitive issue in the use of levetiracetam in childhood epilepsy.
